ARCHIVES

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

ODAC Votes 13:0 to Recommend Perjeta for Accelerated Approval

September 13, 2013

In Brief: Senate Subcommittee Vote: $950 Million Plus training DeVita Needs New Clinical Assistant

July 21, 1978

Kentucky Okays Cancer Commission, $1 Million Budget

April 21, 1978

In Brief: Lasker awards Recognizes Six Scientists; NCAB Honors Vande Woude for Work At NCI

October 1, 1999

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

September 26, 2014

ASPO Hears Proposals For Economic Attacks On Tobacco Industry

April 7, 1989